CTX310 Lipid Disorder: Phase 1 Trial Shows Prom...

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Advancing Kidney Transplant Transparency Through Patient Involvement
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
AI in South African Healthcare: Professionals’ Confidence in Reducing A...
Shifting Toward Sustainable Reimbursement Models in South Africa’s Heal...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 202...
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...